vs
Side-by-side financial comparison of Journey Medical Corp (DERM) and Hyperscale Data, Inc. (GPUS). Click either name above to swap in a different company.
Hyperscale Data, Inc. is the larger business by last-quarter revenue ($26.9M vs $16.1M, roughly 1.7× Journey Medical Corp). Journey Medical Corp runs the higher net margin — -7.8% vs -112.0%, a 104.2% gap on every dollar of revenue. On growth, Hyperscale Data, Inc. posted the faster year-over-year revenue change (38.4% vs 27.3%). Over the past eight quarters, Journey Medical Corp's revenue compounded faster (11.0% CAGR vs -16.3%).
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
Hyperscale Data, Inc. provides GPU-accelerated computing infrastructure and cloud solutions tailored for AI development, big data processing, and high-performance computing workloads. It primarily serves AI startups, large technology firms, and cloud service providers across North America and the Asia-Pacific region, delivering scalable, high-efficiency computing resources to support complex data processing needs.
DERM vs GPUS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.1M | $26.9M |
| Net Profit | $-1.2M | $-30.1M |
| Gross Margin | — | 14.5% |
| Operating Margin | -2.8% | -117.8% |
| Net Margin | -7.8% | -112.0% |
| Revenue YoY | 27.3% | 38.4% |
| Net Profit YoY | -182.0% | -6670.3% |
| EPS (diluted) | $-0.04 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.1M | $26.9M | ||
| Q3 25 | $17.0M | $24.3M | ||
| Q2 25 | $15.0M | $25.9M | ||
| Q1 25 | $13.1M | $25.0M | ||
| Q4 24 | $12.6M | $19.4M | ||
| Q3 24 | $14.6M | $31.1M | ||
| Q2 24 | $14.9M | $17.8M | ||
| Q1 24 | $13.0M | $38.4M |
| Q4 25 | $-1.2M | $-30.1M | ||
| Q3 25 | $-2.3M | $-13.0M | ||
| Q2 25 | $-3.8M | $-19.1M | ||
| Q1 25 | $-4.1M | $-4.2M | ||
| Q4 24 | $1.5M | $-445.0K | ||
| Q3 24 | $-2.4M | $-25.5M | ||
| Q2 24 | $-3.4M | $-33.9M | ||
| Q1 24 | $-10.4M | $3.7M |
| Q4 25 | — | 14.5% | ||
| Q3 25 | — | 25.8% | ||
| Q2 25 | — | 23.7% | ||
| Q1 25 | — | 21.1% | ||
| Q4 24 | 82.3% | 6.5% | ||
| Q3 24 | 63.9% | 27.5% | ||
| Q2 24 | 56.0% | -21.3% | ||
| Q1 24 | 47.7% | 47.4% |
| Q4 25 | -2.8% | -117.8% | ||
| Q3 25 | -9.0% | -57.8% | ||
| Q2 25 | -19.2% | -39.2% | ||
| Q1 25 | -25.3% | -25.5% | ||
| Q4 24 | 17.7% | -46.8% | ||
| Q3 24 | -19.8% | -79.2% | ||
| Q2 24 | -19.7% | -151.4% | ||
| Q1 24 | -77.4% | 9.5% |
| Q4 25 | -7.8% | -112.0% | ||
| Q3 25 | -13.6% | -53.5% | ||
| Q2 25 | -25.3% | -73.7% | ||
| Q1 25 | -31.0% | -16.8% | ||
| Q4 24 | 12.1% | -2.3% | ||
| Q3 24 | -16.3% | -82.3% | ||
| Q2 24 | -22.6% | -190.7% | ||
| Q1 24 | -80.1% | 9.7% |
| Q4 25 | $-0.04 | — | ||
| Q3 25 | $-0.09 | $-0.39 | ||
| Q2 25 | $-0.16 | $-2.66 | ||
| Q1 25 | $-0.18 | — | ||
| Q4 24 | $0.10 | $-8.78 | ||
| Q3 24 | $-0.12 | $-24.82 | ||
| Q2 24 | $-0.17 | $-37.81 | ||
| Q1 24 | $-0.53 | $3.32 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.1M | $13.1M |
| Total DebtLower is stronger | $25.3M | $83.1M |
| Stockholders' EquityBook value | $31.9M | $119.8M |
| Total Assets | $94.6M | $313.7M |
| Debt / EquityLower = less leverage | 0.79× | 0.69× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.1M | $13.1M | ||
| Q3 25 | $24.9M | $24.8M | ||
| Q2 25 | $20.3M | $5.9M | ||
| Q1 25 | $21.1M | $4.2M | ||
| Q4 24 | $20.3M | $4.5M | ||
| Q3 24 | $22.5M | $7.9M | ||
| Q2 24 | $23.9M | $9.6M | ||
| Q1 24 | $24.1M | $18.9M |
| Q4 25 | $25.3M | $83.1M | ||
| Q3 25 | $25.2M | $80.0M | ||
| Q2 25 | $25.1M | $88.5M | ||
| Q1 25 | $25.0M | $92.8M | ||
| Q4 24 | $24.9M | $96.7M | ||
| Q3 24 | $19.8M | $104.8M | ||
| Q2 24 | $19.7M | $106.8M | ||
| Q1 24 | $14.7M | $30.0M |
| Q4 25 | $31.9M | $119.8M | ||
| Q3 25 | $25.9M | $55.9M | ||
| Q2 25 | $19.2M | $5.5M | ||
| Q1 25 | $21.5M | $6.3M | ||
| Q4 24 | $20.1M | $8.6M | ||
| Q3 24 | $10.9M | $2.7M | ||
| Q2 24 | $11.3M | $26.7M | ||
| Q1 24 | $13.0M | $59.0M |
| Q4 25 | $94.6M | $313.7M | ||
| Q3 25 | $85.2M | $242.4M | ||
| Q2 25 | $81.2M | $213.5M | ||
| Q1 25 | $85.0M | $218.5M | ||
| Q4 24 | $80.2M | $220.8M | ||
| Q3 24 | $64.0M | $231.5M | ||
| Q2 24 | $65.2M | $270.8M | ||
| Q1 24 | $66.6M | $299.8M |
| Q4 25 | 0.79× | 0.69× | ||
| Q3 25 | 0.97× | 1.43× | ||
| Q2 25 | 1.30× | 16.06× | ||
| Q1 25 | 1.16× | 14.71× | ||
| Q4 24 | 1.24× | 11.19× | ||
| Q3 24 | 1.81× | 38.41× | ||
| Q2 24 | 1.75× | 4.00× | ||
| Q1 24 | 1.13× | 0.51× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.3M | $-37.7M |
| Free Cash FlowOCF − Capex | — | $-56.2M |
| FCF MarginFCF / Revenue | — | -208.7% |
| Capex IntensityCapex / Revenue | — | 68.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-87.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.3M | $-37.7M | ||
| Q3 25 | $-2.4M | $-17.8M | ||
| Q2 25 | $-942.0K | $-3.1M | ||
| Q1 25 | $-2.8M | $-4.0M | ||
| Q4 24 | $2.2M | $-9.2M | ||
| Q3 24 | $-1.2M | $3.7M | ||
| Q2 24 | $-5.2M | $-3.7M | ||
| Q1 24 | $-5.0M | $-10.2M |
| Q4 25 | — | $-56.2M | ||
| Q3 25 | — | $-20.6M | ||
| Q2 25 | — | $-3.5M | ||
| Q1 25 | — | $-6.8M | ||
| Q4 24 | — | $-9.3M | ||
| Q3 24 | — | $2.6M | ||
| Q2 24 | — | $-5.9M | ||
| Q1 24 | — | $-11.6M |
| Q4 25 | — | -208.7% | ||
| Q3 25 | — | -84.5% | ||
| Q2 25 | — | -13.5% | ||
| Q1 25 | — | -27.3% | ||
| Q4 24 | — | -47.6% | ||
| Q3 24 | — | 8.4% | ||
| Q2 24 | — | -33.4% | ||
| Q1 24 | — | -30.3% |
| Q4 25 | — | 68.6% | ||
| Q3 25 | — | 11.5% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 11.5% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | — | 3.6% | ||
| Q2 24 | — | 12.6% | ||
| Q1 24 | — | 3.7% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.46× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -2.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
GPUS
| Transferred Over Time | $10.4M | 39% |
| Revenue From Mined Crypto Assets At Sentinum Owned And Operated Facilities | $5.8M | 21% |
| Hotel And Real Estate Operations | $4.8M | 18% |
| Other | $4.0M | 15% |
| Turn On Green | $2.0M | 7% |
